106-120 of 266
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
NeuroFrontiersQuantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
NeuroFrontiersCardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Project Oncology®Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Project Oncology®Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Project Oncology®Balancing Benefits and Risks in Emerging Sickle Cell Therapies
- advertisement
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Project Oncology®The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Project Oncology®Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
On the Frontlines of CIDPIdentifying CIDP: A Guide to Risk Profiles and Clinical Presentation
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease
- advertisement
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Identifying C3G: Key Diagnostic Considerations and Challenges
On the Frontlines of C3GIdentifying C3G: Key Diagnostic Considerations and Challenges
Transforming C3G Care: New Advances in Targeted Treatment
On the Frontlines of C3GTransforming C3G Care: New Advances in Targeted Treatment
